Analysis of the National Liver Disease State of the art

THEBERATheodor Bilharz into the European Research Area

FP7 ERAWIDE INCO Project 2010-6-2

Sanaa BotrosTheodor Bilharz Research Institute

THEBERA Coordinator

“Priority Needs and Future Guidelines for Liver Research in

Egypt and EC role in International Cooperation”

Stakeholders Meeting Cairo, 5th December,

2013

THEBERA Objective

Strengthen the capacity of Theodor Bilharz Research Institute (TBRI) for participation in European health research initiatives by expanding cooperation with the ERA while realizing it as an International Excellence Centre for liver disease research/management.

Stakeholders Meeting Cairo, 5th December,

2013

“Priority Needs and Future Guidelines for Liver Research in

Egypt and EC role in International Cooperation”

THEBERA Partner Organizations

Theodor Bilharz Research Institute (TBRI): A medical governmental research institute focusing on management of endemic diseases

Academy of Scientific Research and Technology (ASRT): A non profit organization providing public service by ensuring independent assessment of sciences

Europe for Business Ltd (EFB): A high growth knowledge Co., providing support to PP organizations in product innovation and R&D projects

PISA University (UNIPI): A regional referral center for major hepatobiliary and liver transplant surgery with large liver transplant program

Stakeholders Meeting Cairo, 5th December,

2013

“Priority Needs and Future Guidelines for Liver Research in

Egypt and EC role in International Cooperation”

THEBERA Scientific Activities

M1

M1

M42

M42

WP1 (lead TBRI) : Project Management

WP6 (lead ASRT): Dissemination and Network Facilitation

WP2 Analyze the current Sate of the Art

regarding liver disease

WP5:THEBERA aims to

establish TBRI Excellence Centre for liver disease

research/management

WP3

Build capacity for

International Cooperation

WP4 Capacity building for liver disease Business Plan based on WP2 &

similar EU experience

Stakeholders Meeting Cairo, 5th December,

2013

“Priority Needs and Future Guidelines for Liver Research in

Egypt and EC role in International Cooperation”

Analysis of National Liver Disease State of the Art www.thebera.eg.net

Objectives How far researchers, research work conducted, health system tackling liver disease served the

national health policy. Were plans established conducive to develop appropriate platforms to control infection,

properly manage liver disease and set up plans for development and rationalization for use of vaccines, diagnostics and drugs.

Analysis involved Current policies & programs (objectives, evidence -based, action taken & outcome) , funding

needs & offers, cooperation patterns and actors. Researchers , research conducted, health systems research tackling liver disease.

Stakeholders Meeting Cairo, 5th December,

2013

“Priority Needs and Future Guidelines for Liver Research in

Egypt and EC role in International Cooperation”

Analysis of National Liver Disease State of the Artwww.thebera.eg.net

Approach Liver diseases: Context, Tools and Actors. Strategies: “Egyptian National Control Strategy (NCS) for viral hepatitis”. Socioeconomic burden of HCV in Egypt. Publications of national institutes on liver disease published nationally &internationally. 2005-2010. Coordinating institute “TBRI” publications & projects.

Publications Analysis National institutes’ number of publications (national & international). Number of collaborating international organizations. Quality of publications and details of international affiliations. Most targeted journals, liver disease subject and research topic . Relevancy of national institutes research to NCS on viral hepatitis.

Stakeholders Meeting Cairo, 5th December,

2013

“Priority Needs and Future Guidelines for Liver Research in

Egypt and EC role in International Cooperation”

Volume of international and national research publications on liver research over the period 2005-2010

Stakeholders Meeting Cairo, 5th December,

2013

“Priority Needs and Future Guidelines for Liver Research in

Egypt and EC role in International Cooperation”

11.70%

13.50% 14.90%16%

20.60%

23.30%

International

2005 2006 2007 2008 2009 2010Year

Perc

en

tag

e

20.60%

39.90%

18.50%

15.20%

5.40%

0.50%

National

2005 2006 2007 2008 2009 2010Year

Perc

en

tag

e

Volume of international and national publications on liver disease according to field of research over the period

2005-2010

Stakeholders Meeting Cairo, 5th December,

2013

“Priority Needs and Future Guidelines for Liver Research in

Egypt and EC role in International Cooperation”

37.20%

26.20%

18.20%

16.20%

0.80% 0.70% 0.70%

International

Diag./Prog. Therap./Manag.

Drug Study Epid./Prev.

Soc.Medicine Blood Safety

Health Care Manag.

Field of Research

Perc

en

tag

e

52.50%

27.40%

11%

6.20%

1.30% 0.90% 0.70%

National

Diag./Prog. Epid./Prev.

Therap./Manag. Drug Study

Blood Safety Health Care Manag.

Soc.Medicine

Field of Research

Perc

en

tag

e

Volume of international and national publications according to studied liver disease over the period 2005-2010

Stakeholders Meeting Cairo, 5th December,

2013

“Priority Needs and Future Guidelines for Liver Research in

Egypt and EC role in International Cooperation”

N.B: The small slices are ranging from 1.7% to 0.2% and represent HEV, Hep. Tox., Fatty Liver, NAFLD, HGV and NASH respectively.

HCV 39.10

%

HCC 19.30%

CLD 9.70%

HBV 9.50%

Others 7.40%Schisto 4.70%

HAV 3.20%

Liver Transplantation 2.30%

International

HCV 29.22%

Schisto 25.75%HCC 14.69%

CLD 10.83%

HBV 6.94%

Hep. Not Classi-fied 2.18%

NAFLD 2.02%

National

N.B: The small slices (1.61% - 0.16%) represent fascioliasis, HCV combined research with other hepatitis viruses or schistosomiasis, other viral hepatitis subtypes, liver transplantation and NASH.

Salient Findings Collaborating international organizations comprised 56% with 88% of leading scientists

affiliated to Egyptian universities and institutions. Most of researches published internationally targeted diagnostic/prognostic aspects. Survey assessments research aspects were acceptable to evaluate the liver disease

problem in Egypt but for surveillance sentinel groups and mathematical modeling may better timely explain the situation.

Majority of research topics targeted HCV, HCC, HBV and CLD the least studied was social medicine, health care management and blood safety.

Community acquired risk factors for infection were efficiently studied contrary to hospital acquired ones.

Drug studies were mainly on natural products targeting chiefly hepato-protectives. Editorial on therapeutic management and liver transplantation were poorly represented.

Stakeholders Meeting Cairo, 5th December,

2013

“Priority Needs and Future Guidelines for Liver Research in

Egypt and EC role in International Cooperation”

Liver disease priority needsGovernance Oversight body to co-ordinate between entities providing health services for liver

disease patients e.g. MoHP, MoSR, MoHE and HIO.

Finance Better tracing of different liver institute domestic funding to forecast future funding

requirements with efforts for fund raising; national and international.

Networking Academic institutions, private, public sectors, international organizations and policy

makers , blood banks and build up of integrated information system for surveillance and patient follow-up.

Education/Training Programs for training more physicians on management of liver diseases , supportive

staff “nurses and technicians” and a continued medical education program for senior staff.

Stakeholders Meeting Cairo, 5th December,

2013

“Priority Needs and Future Guidelines for Liver Research in

Egypt and EC role in International Cooperation”

Policy Strategies to increase the awareness and knowledge of the general population on modes

of transmission and methods of prevention. Expanding infection control program in public and private healthcare facilities, innovative

solutions for better control of hospital acquired viral infection and a plan to control small blood banks.

Efficient notification system to audit and register private sector with respect to acute infection, chronic liver disease, application of infection control program and injection safety procedures.

Allocation of budget to narrow the time lapse between different prevalence surveys to make best benefit of surveillance system.

A program to assess the efficacy of HBV vaccination in children, sentinel groups and high risk groups.

Solving the technical and financial constraints limiting liver transplantation.

Stakeholders Meeting Cairo, 5th December,

2013

“Priority Needs and Future Guidelines for Liver Research in

Egypt and EC role in International Cooperation”

Technical/Research Establishment of proper database system. Operational research concerning scaling up of case detection and improving access to

medical care. Meta-data analysis studies to choose the highest ranking biomarkers for proper

management of liver disease . Mathematical modeling for estimation of future burden of HCV and HBV infections to

upscale the allocated budget according to expected needs. New tools adaptable or as modification from existing R&D , new makeovers e.g.

homemade shorter course , more cost effective interferon and the availability of antiviral syrup for pediatric use.

Social rehabilitation program for patients during medical and after major surgery with interventions to improve quality of life.

Increasing the number of liver treatment centers, availability of tools for management of liver diseases at remote health facilities e.g. endoscopies, sonar and labs for PCR.

Stakeholders Meeting Cairo, 5th December,

2013

“Priority Needs and Future Guidelines for Liver Research in

Egypt and EC role in International Cooperation”

Thank You

Stakeholders Meeting Cairo, 5th December,

2013

“Priority Needs and Future Guidelines for Liver Research in

Egypt and EC role in International Cooperation”